Table 2.

EGFR and FGFR inhibitors and the incidence of corneal subepithelial changes

	Classification	Drug	Description	Total prescribed patients	patients referred to OPH (%)	Patients With corneal epithelial changes
EGFR inhibitor	1st Generation	Erlotinib	EGFR TKI which binds in a reversible fashion to the ATP binding site of the receptor	2296	314 (13.68)	0
		Gefitinib	EGFR TKI which binds to ATP binding site of the receptor	2772	453 (16.34)	0
	2nd Generation	Afatinib	selectively and irreversibly binds to and inhibits the EGFR 1, 2, and 4, and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations.	302	26 (8.61)	0
	3rd Generation	Osimertinib	a third generation EGFR inhibitor which shows 200-fold selectivity for T790 M/L858R protein over wild-type EGFR	202	158 (78.22)	1 (0.50%)
		Olmutinib	EGFR mutation-specific tyrosine kinase inhibitor	79	28 (35.44)	0
		YH25448	a Highly Selective third Generation EGFR TKI	10	10 (100.00)	0
		Naquotinib	binds to and inhibits the activity of mutant forms of EGFR, including the T790 M EGFR mutant	11	11 (100.00)	0
		Rociletinib	inhibits T790 M, a secondary acquired resistance mutation, as well as other mutant EGFRs	11	4 (36.36)	0
	BBB penetrating	AZD3759	a novel EGFR tyrosine kinase inhibitor with high capability to penetrate the BBB	12	12 (100.00)	0
	EGFR mAb	Cetuximab	a chimeric monoclonal antibody which binds to and inhibits EGFR	974	89 (9.14)	0
		JNJ-61186372	bispecific antibody that targets EGFR and cMet	9	5 (55.56)	0
	Ab-ADC	ABT-414	an investigational compound targeting a tumor-selective EGFR epitope	5	5 (100.00)	5 (100.0%)
	multi TKI	Vandetanib	a selective inhibitor of EGFR and vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase	19	10 (52.63)	3 (15.79%)
FGFR inhibitor		ASP5878	a novel drug which inhibits all FGFRs targeting FGF19-expressing HCC	2	2 (100.00)	1 (50.0%)
	FGFR mAb	FPA144	an enhanced Monoclonal Antibody against FGFR2b	11	11 (100.00)	2 (18.18%)
	multi TKI	Pazopanib	a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis (inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, beta receptors, cytokine receptor)	2	1 (50.00)	0
		Regorafenib	Multikinase inhibitor (VEGFR 1–3, PDGFR-alpha, PDGFR-beta, etc)	154	22 (14.29)	0

EGFR epidermal growth factor receptor, ATP adenosine triphosphate, FGFR fibroblast growth factor receptor, OPH ophthalmology department, BBB blood-brain barrier, mAb monoclonal antibody, cMet tyrosine-protein kinase Met, Ab-ADC antibody-drug conjugate, TKI tyrosine kinase inhibitor, VEGFR Vascular Endothelial Growth Factors, PDGFR Platelet-derived growth factor receptor